カテゴリ： GlobalData, アメリカ, 企業調査

Tesaro Inc (TSRO)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Tesaro Inc (TSRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014186
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：79
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates, comprising rolapitant, niraparib, and the product candidates under its immuno-oncology platform. VARUBI, the company’s first commercial product is approved for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. The company distributes the product in the US principally through specialty distributors and specialty pharmacy channel. Its development portfolio includes novel cancer and supportive care product candidates in various development stages. Tesaro is headquartered in Waltham, Massachusetts, the US.

Tesaro Inc (TSRO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Tesaro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Tesaro Inc, Medical Devices Deals, 2011 to YTD 2017 10
Tesaro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Tesaro Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
TESARO Secures US$101 Million In Series B Venture Financing 13
Partnerships 15
Evotec and Tesaro Enter into Agreement 15
OncoQuest Enters into Agreement with Tesaro 16
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 17
Licensing Agreements 18
Millennium Pharma Enters into Licensing Agreement with Tesaro 18
Zai Lab Enters into Licensing Agreement with Tesaro 19
Janssen Biotech Enters into Licensing agreement with Tesaro 20
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 21
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 22
Tesaro Amends Licensing Agreement With AnaptysBio 23
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 24
Tesaro Enters Into Licensing Agreement With Amgen 25
Equity Offering 26
Tesaro Raises USD236.3 Million in Public Offering of Shares 26
Tesaro Raises USD433.2 Million in Public Offering of Shares 28
Tesaro Raises USD50 Million in Private Placement of Shares 30
Tesaro Raises up to USD155 Million in Private Placement of Shares 31
Tesaro Raises USD191.5 Million in Public Offering of Shares 33
Tesaro Completes Public Offering Of Shares For US$100.8 Million 35
Tesaro Completes Public Offering Of Common Stock For US$98 Million 36
Tesaro Announces Partial Exercise Of Underwriter’s Option For IPO For US$87 Million 37
Debt Offering 39
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 39
Acquisition 41
Tesaro May Sell Itself 41
Tesaro Inc – Key Competitors 42
Tesaro Inc – Key Employees 43
Tesaro Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
Nov 07, 2017: TESARO Announces Third-Quarter 2017 Operating Results 45
Aug 08, 2017: TESARO Announces Second-Quarter 2017 Operating Results 47
May 09, 2017: TESARO Announces First-Quarter 2017 Operating Results 49
Feb 28, 2017: TESARO Announces Fourth-Quarter 2016 Operating Results 51
Nov 03, 2016: TESARO Announces Third-Quarter 2016 Operating Results 53
Aug 04, 2016: Tesaro Announces Second-Quarter 2016 Operating Results 55
May 05, 2016: TESARO Announces First-Quarter 2016 Operating Results 57
Feb 25, 2016: TESARO Announces Fourth-Quarter 2015 Operating Results 59
Corporate Communications 61
Apr 04, 2016: TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors 61
Product News 62
09/06/2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting 62
06/23/2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer 63
05/18/2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting 64
02/23/2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant) 65
01/11/2016: Tesaro Outlines Business Priorities And Strategic Outlook For 2016 66
Product Approvals 68
Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA 68
Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing 69
Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA 70
Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency 71
Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration 72
Clinical Trials 73
Aug 08, 2016: Cancer Treatment Centers of America at Western Regional Medical Center is the first site in the world for new investigational anti-cancer treatment 73
Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing 74
Mar 29, 2016: TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042 75
Other Significant Developments 76
Jun 03, 2017: TESARO Provides Business and Pipeline Update at ASCO Investor Briefing 76
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79

List of Tables
Tesaro Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Tesaro Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Tesaro Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Tesaro Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Tesaro Inc, Medical Devices Deals, 2011 to YTD 2017 10
Tesaro Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
TESARO Secures US$101 Million In Series B Venture Financing 13
Evotec and Tesaro Enter into Agreement 15
OncoQuest Enters into Agreement with Tesaro 16
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 17
Millennium Pharma Enters into Licensing Agreement with Tesaro 18
Zai Lab Enters into Licensing Agreement with Tesaro 19
Janssen Biotech Enters into Licensing agreement with Tesaro 20
Tesaro Enters into Licensing Agreement with MD Anderson Cancer Center 21
Jiangsu Hengrui Medicine Enters into Licensing Agreement with Tesaro 22
Tesaro Amends Licensing Agreement With AnaptysBio 23
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 24
Tesaro Enters Into Licensing Agreement With Amgen 25
Tesaro Raises USD236.3 Million in Public Offering of Shares 26
Tesaro Raises USD433.2 Million in Public Offering of Shares 28
Tesaro Raises USD50 Million in Private Placement of Shares 30
Tesaro Raises up to USD155 Million in Private Placement of Shares 31
Tesaro Raises USD191.5 Million in Public Offering of Shares 33
Tesaro Completes Public Offering Of Shares For US$100.8 Million 35
Tesaro Completes Public Offering Of Common Stock For US$98 Million 36
Tesaro Announces Partial Exercise Of Underwriter’s Option For IPO For US$87 Million 37
Tesaro Raises USD201.3 Million in Public Offering of 3% Notes Due 2021 39
Tesaro May Sell Itself 41
Tesaro Inc, Key Competitors 42
Tesaro Inc, Key Employees 43
Tesaro Inc, Subsidiaries 44

★海外企業調査レポート[Tesaro Inc (TSRO)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Apogenix AG：製薬・医療：M&Aディール及び事業提携情報
    Summary Apogenix AG (Apogenix) is a developer of immuno-oncology medicines for the treatment of oncological and malignant hematological diseases. The company’s pipeline drug candidates under clinical development include APG101, a CD95 ligand inhibitor for the treatment of glioblastoma and myelodyspl …
  • Flower Orthopedics Corp：医療機器：M&Aディール及び事業提携情報
    Summary Flower Orthopedics Corp (Flower Orthopedics) is a medical equipment provider that offers orthopedic devices. The company offers instrument kits which include K-wire kits, olive wire kits, guide wire kits, drill bit kits, lag screw kits, cannulated drill bits, trials and cannulated countersin …
  • Dis-Chem Pharmacies Limited (DCP)：企業の財務・戦略的SWOT分析
    Dis-Chem Pharmacies Limited (DCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • JHL Biotech Inc：医療機器：M&Aディール及び事業提携情報
    Summary JHL Biotech Inc (JHL Biotech) is a biologic medicines provider. The company offers cell line construction, process development, manufacturing, quality and regulatory services. It offers products such as biosimilar rituximab, biosimilar dornase alfa, biosimilar bevacizumab, biosimilar trastuz …
  • Tata Chemicals Ltd (TATACHEM)：企業の財務・戦略的SWOT分析
    Summary Tata Chemicals Ltd (TCL) operates as a chemical company engaged in offering industry, living, and farm essential chemicals. The company's products include dals, consumer salt, water purifier, soda ash, spices, sodium bicarbonate, allied chemicals, industrial salt, customized fertilizers, cem …
  • Pinnacle Biologics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Pinnacle Biologics Inc (Pinnacle Biologics), a subsidiary of Concordia Healthcare Corp. is a drug company that develops and markets photodynamic therapy products. The company offers products such as PHOTOFRIN PI, OPTIGUIDE PI, ETHYOL PI and DIOMED products. Its OPTIGUIDE PI products comprise …
  • Celcuity Inc (CELC)：企業の製品パイプライン分析
    Summary Celcuity Inc (Celcuity) is a cellular analysis company that develops companion diagnostic tests to identify new patient populations for targeted therapies. The company’s CELx signaling function diagnostic platform utilizes a patient’s living tumor cells to identify the specific abnormal cell …
  • Rizzani De Eccher S.P.A.：企業の戦略・SWOT・財務分析
    Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report Summary Rizzani De Eccher S.P.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Maximus Inc.：企業の戦略・SWOT・財務情報
    Maximus Inc. - Strategy, SWOT and Corporate Finance Report Summary Maximus Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Citizen Watch Co., Ltd. (7762)：企業の財務・戦略的SWOT分析
    Citizen Watch Co., Ltd. (7762) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Metropolis Healthcare Ltd-医療機器分野：企業M&A・提携分析
    Summary Metropolis Healthcare Ltd (Metropolis Healthcare) is a healthcare service provider that provides pathology testing services. The center provides tests and test combinations, which ranges from routine screening tests to specialized molecular and genetic assays. It also specializes in clinical …
  • EDF Energy Holdings Ltd：電力：M&Aディール及び事業提携情報
    Summary EDF Energy Holdings Ltd (EDF Energy), a subsidiary of Electricite de France SA, is an energy utility and is one of the major producers of low carbon electricity in the UK. The company together with its subsidiaries carries out the generation, provision and supply of electricity and gas. It g …
  • Mercuria Energy Group Ltd：企業のM&A・事業提携・投資動向
    Mercuria Energy Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mercuria Energy Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Tecan Group Ltd (TECN)：医療機器：M&Aディール及び事業提携情報
    Summary Tecan Group Ltd (Tecan) is a provider of automated laboratory instruments and solutions for use in basic and translational research, clinical diagnostics, and drug discovery. The company develops, manufactures, and markets automated workflow solutions for laboratories and instrumentation sup …
  • Toyo Seikan Group Holdings, Ltd.：企業の戦略・SWOT・財務分析
    Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyo Seikan Group Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Episurf Medical AB (EPIS B)：企業の製品パイプライン分析
    Summary Episurf Medical AB (Episurf Medical), formerly Diamorph Medtech AB is a medical technology company that provides patient-specific treatments of painful joint injuries. It offers diagnosis and design of implants and surgical instruments. Its products include Episealer Femoral Twin, Episealer …
  • The Hain Celestial Group Inc (HAIN)：企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Pental Limited (PTL)：企業の財務・戦略的SWOT分析
    Pental Limited (PTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Tampa Electric Co：企業の戦略的SWOT分析
    Tampa Electric Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • VentiRx Pharmaceuticals Inc-製薬・医療分野：企業M&A・提携分析
    Summary VentiRx Pharmaceuticals Inc (VentiRx) is a biopharmaceutical company that develops and commercializes drugs for the treatment of respiratory, autoimmune diseases and cancer. The company develops toll like receptor 8 agonist and antagonists for the treatment of cancer, respiratory and autoimm …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆